ADTX · Aditxt, Inc.
$0.00
-0.01 (-80.00%)
At close · Jun 25
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of these factors, we believe that this creates substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Market Cap
$4.99M
Shares
815,921
ADTX metrics
39 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.00
Market cap
$4.99M
Price action
19 metricsPrice change (1W)
-80.0%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Beta
—
RSI (14D)
4.3
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
900.84M
Relative volume
0.4
Average dollar volume
$16.96M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
815,921
Valuation
12 metricsP / E (TTM)
0.0
Trailing earnings · reciprocal yield 8,306,454,000.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
348.1×
reciprocal yield 0.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,066.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
19.9%
Operating margin
-127,821.4%
Trailing 12 months
Net margin
-371,093.9%
Gross profit (TTM)
$2,852
Operating profit (TTM)
−$18.32M
Net income (TTM)
−$53.20M
Trailing 12 months
Diluted EPS (TTM)
$166,129.08
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+1,094.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$14,336
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+69,465.5%
Year over year · more shares
Revenue CAGR (3Y)
-84.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-382.5%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-33.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$268,852
Total assets
$13.91M
Total debt
$5
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$18.55M
Capital expenditures (TTM)
—
R&D (TTM)
$3.03M
SG&A (TTM)
$1.15M
Stock compensation (TTM)
—
R&D / revenue
21,149.6%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
−$1,246
Insider-sentiment score
61 / 100
Risk flags
1 metricsGoing concern
Flagged